These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6142671)

  • 21. Current status of drug therapy for inflammatory bowel disease.
    Peppercorn MA
    Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful desensitization for azathioprine skin rash in a patient with severe Crohn's disease.
    Lavaud F; Abdelli N; Thiefin G
    Dig Dis Sci; 1997 Apr; 42(4):823. PubMed ID: 9125656
    [No Abstract]   [Full Text] [Related]  

  • 23. [Desensitization to salicylazosulfapyridine (Salazopyrin) in a patient with ulcerative colitis].
    Chiba M; Murata M; Ihzuka M; Ohta H; Arakawa H; Masamune O; Ohkubo M
    Nihon Shokakibyo Gakkai Zasshi; 1986 Jan; 83(1):113-6. PubMed ID: 2871206
    [No Abstract]   [Full Text] [Related]  

  • 24. Human leukocyte antigen genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: a pilot study.
    Lee B; Yu HJ; Kang ES; Lee M; Lee J
    Pediatr Neurol; 2014 Aug; 51(2):207-14. PubMed ID: 25079569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulfasalazine toxic reactions. Hepatitis, fever, and skin rash with hypocomplementemia and immune complexes.
    Mihas AA; Goldenberg DJ; Slaughter RL
    JAMA; 1978 Jun; 239(24):2590-1. PubMed ID: 26816
    [No Abstract]   [Full Text] [Related]  

  • 28. Sulfasalazine-induced agranulocytosis.
    Jacobson IM; Kelsey PB; Blyden GT; Demirjian ZN; Isselbacher KJ
    Am J Gastroenterol; 1985 Feb; 80(2):118-21. PubMed ID: 2857524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Axonal neuropathy and salazosulfapyridine: slow-acetylator phenotype].
    Blin O; Sangla I; Jouglard J; Cottin C; Pellissier JF; Serratrice G
    Rev Neurol (Paris); 1992; 148(2):154-6. PubMed ID: 1351312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulphasalazine desensitisation in patients with arthritis.
    McCarthy C; Coughlan R
    Ir J Med Sci; 1994 May; 163(5):238-9. PubMed ID: 7913919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug rash with eosinophilia and systemic symptoms secondary to sulfasalazine.
    Rosenbaum J; Alex G; Roberts H; Orchard D
    J Paediatr Child Health; 2010 Apr; 46(4):193-6. PubMed ID: 20546480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatotoxicity after treatment with sulfasalazine.
    Haines JD
    Postgrad Med; 1986 May; 79(6):193-4, 197-8. PubMed ID: 2871549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
    Goldstein PD; Alpers DH; Keating JP
    J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tubular-interstitial nephritis and fibrosing alveolitis induced by sulfasalazine in ulcerative colitis].
    Avdeev VG; Fomin VV; Popova EN; Iurkevich LIu; Osipenko VI; Sokolina IA; Popova IA
    Ter Arkh; 2006; 78(1):77-9. PubMed ID: 16512452
    [No Abstract]   [Full Text] [Related]  

  • 35. Hemolytic anemia in patients receiving sulfasalazine.
    Goodacre RL; Ali MA; Vanderlinden B; Hamilton JD; Castelli M; Seaton T
    Digestion; 1978; 17(6):503-8. PubMed ID: 30666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulfasalazine therapy in inflammatory bowel disease.
    Das KM
    Gastroenterol Clin North Am; 1989 Mar; 18(1):1-20. PubMed ID: 2563989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
    Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
    Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulphasalazine: a review of 40 years' experience.
    Watkinson G
    Drugs; 1986; 32 Suppl 1():1-11. PubMed ID: 2877847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [40 years of salazosulfapyridine. Is end in sight?].
    van Hees PA; van Tongeren JH
    Ned Tijdschr Geneeskd; 1982 Oct; 126(44):2014-8. PubMed ID: 6129576
    [No Abstract]   [Full Text] [Related]  

  • 40. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.